Comparison of Ki-67 equivalent antibodies

被引:61
|
作者
Lindboe, CF [1 ]
Torp, SH
机构
[1] Vest Agder Cent Hosp, Dept Pathol, N-4604 Kristiansand, Norway
[2] Univ Trondheim Hosp, Norwegian Univ Sci & Technol, Dept Lab Med & Pathol, N-7006 Trondheim, Norway
关键词
D O I
10.1136/jcp.55.6.467
中图分类号
R36 [病理学];
学科分类号
100104 ;
摘要
Aims: To compare commercially available Ki-67 equivalent antibodies with regard to qualitative and quantitative immunohistochemical staining characteristics. Methods: The following antibodies were used: monoclonal MIB-1 (Immunotech), monoclonal MM1 (Novocastra), polyclonal NCL-Ki-67p (Novocastra), and polyclonal Rah Ki-67 (Dako). All immunostainings were evaluated in squamous epithelium from formalin fixed and paraffin wax embedded pharyngeal tonsils. Labelling indices (Lis) were recorded twice to test their reproducibility. Results: By application of all four antibodies the nuclear staining could be either diffuse, granular, or a combination of both (classified as granular in this study). The diffuse pattern generally showed a strong or moderate staining intensity, whereas the granular pattern displayed a continuum from strong to very weak, making it difficult to discriminate between positive and negative nuclei. The diffuse staining pattern was seen in approximately 59% of the nuclei with the MIB-1 antibody and in 35-45% when the other antibodies were used. The following mean Us were recorded: MIB-1, 31%; NCL-Ki-67p, 21%; Rah Ki-67, 17%; and MM1, 14%. The reproducibility was excellent for all four antibodies, with the mean of differences between the two runs of counts ranging from 1.1% to 1.5%. Conclusions: The four tested Ki-67 equivalent antibodies revealed differences in qualitative and quantitative staining characteristics, which resulted in considerable variations in registered Us. The MIB-1 antibody appears to have a higher sensitivity for detecting the Ki-67 antigen than the other three tested antibodies. These differences are important to consider when proliferative activity is determined by the Ki-67 LI.
引用
收藏
页码:467 / 471
页数:5
相关论文
共 50 条
  • [31] The role of Ki-67 in breast cancer
    Mannell, A.
    SOUTH AFRICAN JOURNAL OF SURGERY, 2016, 54 (02) : 10 - 13
  • [32] Ki-67 expression in pulmonary tumors
    Chirieac, Lucian R.
    TRANSLATIONAL LUNG CANCER RESEARCH, 2016, 5 (05) : 547 - 551
  • [33] IMMUNOEXPRESSION OF KI-67 IN PULMONARY HYPOPLASIA
    Dzieniecka, Monika
    Krystosiak, Karolina
    Kulig, Andrzej
    POLISH JOURNAL OF PATHOLOGY, 2013, 64 (02) : 109 - 113
  • [34] Ki-67, a marker of proliferation.
    Guinebretiere, JM
    Sabourin, JC
    ANNALES DE PATHOLOGIE, 1997, 17 (01) : 25 - 30
  • [35] Ki-67 as proliferative marker of thyroid
    Wiwanitkit, V
    INDIAN JOURNAL OF CANCER, 2011, 48 (03)
  • [36] Ki-67 and apoptosis in an embryological model
    Evrard, L
    Louryan, S
    Werry-Huet, A
    VanMuylder, N
    Rooze, M
    Dourov, N
    ANNALES DE PATHOLOGIE, 1998, 18 (05) : 450 - 452
  • [37] Ki-67 Expression in Pulmonary Neuroendocrine
    Barletta, J. A.
    Zellos, L.
    Law, K.
    Sugarbaker, D.
    Rodig, S.
    Chirieac, L. R.
    MODERN PATHOLOGY, 2009, 22 : 349A - 349A
  • [38] The intrinsically disorderly story of Ki-67
    Remnant, Lucy
    Kochanova, Natalia Y.
    Reid, Caitlin
    Cisneros-Soberanis, Fernanda
    Earnshaw, William C.
    OPEN BIOLOGY, 2021, 11 (08)
  • [39] KI-67 EXPRESSION IN VULVAR CARCINOMA
    HENDRICKS, JB
    WILKINSON, EJ
    KUBILIS, P
    DREW, P
    BLAYDES, SM
    MUNAKATA, S
    INTERNATIONAL JOURNAL OF GYNECOLOGICAL PATHOLOGY, 1994, 13 (03) : 205 - 210
  • [40] CYTOPLASMIC KI-67 EXPRESSION - A REPLY
    SCOTT, CS
    FEY, SJ
    LARSEN, PM
    LEUKEMIA, 1989, 3 (05) : 397 - 397